Literature DB >> 6185599

Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin.

M Johns, A Skehill, W R McCabe.   

Abstract

The protection by antisera to O antigens and antigens (lipid A, the Re 595 mutant of Salmonella minnesota, and the J5 mutant of Escherichia coli) of the core portion of endotoxin against lethal challenge with lipopolysaccharide (LPS) was compared. Rabbits immunized with the Re mutant developed antibody that protected mice against challenge with S. minnesota or Salmonella typhosa LPS. Antisera to heterologous O antigen and lipid A were not protective, whereas homologous antisera and antiserum to the Re or J5 mutant protected against lethal challenge. On a volumetric basis, O-specific antiserum was consistently somewhat more protective than antiserum to the Re mutant, which was slightly more protective than antiserum to the J5 mutant. When comparisons were made using passive transfer to similar quantities of hemagglutinating or precipitating antibody, antiserum to the Re mutant was considerably more protective than O-specific antiserum. This greater protection is hypothesized to result from more effective masking of the toxic lipid A moiety by antibody to the rough mutants than by O-specific antibody.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6185599     DOI: 10.1093/infdis/147.1.57

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis.

Authors:  Catherine H Valentine; Judith Hellman; Laura K Beasley-Topliffe; Aranya Bagchi; H Shaw Warren
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 2.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

3.  [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors:  E T Rietschel; H Brade
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

4.  [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors:  E T Rietschel; H Brade
Journal:  Infection       Date:  1987       Impact factor: 3.553

5.  Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor.

Authors:  H S Warren; M L Glennon; N Wainwright; S F Amato; K M Black; S J Kirsch; G R Riveau; R I Whyte; W M Zapol; T J Novitsky
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 6.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

7.  Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model.

Authors:  Qiong Liu; Qing Liu; Jie Yi; Kang Liang; Tian Liu; Kenneth L Roland; Yanlong Jiang; Qingke Kong
Journal:  Int J Med Microbiol       Date:  2016-08-25       Impact factor: 3.473

8.  Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli O111 and its rough mutant J5.

Authors:  R W Vreede; J Leuvenink; A S Bouter; E C Brouwer; J H Marcelis; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

9.  Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin.

Authors:  D T Golenbock; J A Will; C R Raetz; R A Proctor
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

10.  Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time.

Authors:  D E McCallus; N L Norcross
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.